Items tagged with Vaccines
Long-term follow-up of participants in clinical trials of a generic vaccine to reverse advanced type 1 diabetes finds significant clinical benefits, including restoration of near-normal blood sugar levels. Three years after receiving two administrations of the bacillus Calmette-Guérin (BCG) vaccine four weeks apart, all members of a group of adults with longstanding type 1 diabetes showed an improvement in HbA1c to near normal levels – improvement that persisted for the following five years. The study from a Massachusetts General Hospital (MGH) research team – published in npj Vaccines – also reports that the effects of BCG vaccine on blood sugar control appear to depend on a totally novel metabolic mechanism that increases cellular consumption of glucose.
New England Journal of Medicine publishes final results from innovative Phase 2 study showing vaccines can reduce rate of sustained TB infections in adolescents at high risk (post)
Trial offers hope for new revaccination strategies with Bacille Calmette-Guerin (BCG) against TB, the world’s leading infectious disease killer.
Novel vaccine trial design aims to answer key TB questions (post with simple image)
Prevention of infection study underway in South Africa.
The Lancet journals: World TB Day media alert (post with simple image)
For World TB Day 2014, The Lancet group publishes a Series of papers to highlight the need for global collaboration to diagnose, treat, and cure people with tuberculosis.
HIV i-Base/TAG: 2014 Pipeline Report (post with simple image)
Latest annual review on pipeline drugs for adults and children, strategies for cure and prevention for HIV, HCV, TB and vaccine research.
New vaccine shows promise as stronger weapon against both tuberculosis and leprosy (post with simple image)
UCLA-led research finds that a variant of an existing vaccine offers stronger protection against both diseases
Large trial will evaluate vaccine’s ability to prevent tuberculosis disease (post with simple image)
Multi-site study underway in Africa
New vaccines targeting adults and teens are best chance to eliminate TB by 2050 (post with simple image)
Targets to eliminate tuberculosis by 2050 are more likely to be met if new vaccines are developed for adults and adolescents instead of for infants.
TB R&D’s shift to the left (post with simple image)
As the Bill & Melinda Gates Foundation realigns its TB vaccine strategy to focus on early-stage candidate development, equitable access priorities must also be established before large-scale trials are conducted.
Page 11 of 12 · Total posts: 0←First 10 11 12 Last→